Liquid Biopsy Market Boom: Tools, Services, and Diagnostics Unveiled

"Liquid biopsy is a revolutionary, non-invasive method for detecting diseases like cancer through blood samples instead of traditional tissue biopsies. This market is rapidly growing, offering advanced tools, services, and diagnostics that improve early detection, monitoring, and treatment decisions worldwide."

BOSTON, May 13, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the demand for Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets is projected to grow from $4.6 billion in 2024 to $13.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.3% during the forecast period of 2024 to 2029.

This report offers a comprehensive analysis of the global liquid biopsy market, covering tools, services, and diagnostics. It includes market trends, estimates, and CAGR forecasts from 2024 to 2029, using 2023 as the base year. The study explores industry structure, competitive dynamics, key players, product offerings, financials, and strategies. It segments the market by application, analysis purpose, biomarker type, and platform. Regional insights span North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.

Interesting facts:

    --  Liquid biopsies (LBx), primarily used for genetic profiling and therapy
        selection, are now expanding into pharmaceutical research and enhancing
        various aspects of patient care.
    --  Advances in nanotechnology are driving the development of innovative
        sensors and systems for detecting and analyzing liquid biopsy
        biomarkers, potentially offering greater sensitivity and specificity
        than existing techniques.

Factors contributing to the market's growth include:

    1. Advances in liquid biopsy workflow technologies: These are making it
       easier and faster to detect disease-related biomarkers in blood or other
       fluids. These improvements enhance accuracy, reduce processing time, and
       enable earlier diagnosis and better treatment monitoring.
    2. Increasing incidence of cancer: This is due to the world's aging
       populations, lifestyle changes, and environmental influences. This
       growing incidence highlights the need for better screening, early
       detection, and advanced treatment options.
    3. Growing awareness of early cancer detection: More people are learning
       about the importance of detecting cancer early, which can lead to better
       treatment outcomes. Awareness campaigns and improved screening methods
       are helping to catch cancer in its early stages.
    4. Limitations of tissue biopsy: Tissue biopsies are invasive procedures
       that can be painful and risky, requiring surgery or needle extraction.
       They may also miss tumor changes over time, making it harder to track
       disease progression accurately.
    5. Growing significance of precision medicine: Precision medicine tailors'
       treatments to a person's unique genes and disease characteristics. This
       approach helps improve treatment effectiveness and reduces side effects.
    6. Emerging economies: Emerging economies, such as India and Brazil, are
       experiencing rapid economic growth and development. Advances in the
       improving industries, healthcare, and infrastructure are creating new
       opportunities.

Request a sample copy of the global markets for liquid biopsy research tools, services and diagnostics report.

Report Synopsis

     
              Report Metric   
     
              Details



     Base year considered                                                                                          2023



     Forecast period considered 
     2024-2029



     Base year market size                                                                        
            $3.8 billion



     Market size forecast                                                                        
            $13.1 billion



     Growth rate                
     CAGR of 23.3% for the forecast period of 2024-2029



     Segments covered           
     Application, purpose of analysis, biomarker type, platform, and region



     Regions covered              North America, Europe, Asia-Pacific, and the Rest of the World (South America and the
                                    Middle East and Africa)



     Countries covered          
     U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, China, India, Japan



     Market drivers             
     --         Advances in liquid biopsy workflow technologies.

                                 
     --         Increasing incidence of cancer.

                                 
     --         Growing awareness of early cancer detection.

                                 
     --         Limitations of tissue biopsy.

                                 
     --         Growing significance of precision medicine.

                                 
     --         Emerging economies.

Questions addressed:

1. What is the projected market size and growth rate?

The global market for liquid biopsy research tools, services and diagnostics was estimated at $4.6 billion in 2024. It is projected to reach $13.1 billion by the end of 2029, at a CAGR of 23.3% from 2024 to 2029.

2. What segments are covered in the market?

The market segments covered include applications for cancer, and non-invasive prenatal screening. Based on biomarker type and analysis platforms, the market segments include cell free nucleic acids, circulating tumor cells, and NGS, and PCR.

3. Which application type will be dominant throughout the forecast period?

Non-invasive prenatal screening (NIPT) will be the dominant application type.

4. Which region has the largest market share?

North America holds the largest share of the market.

Market leaders include:

    --  Bio-Rad Laboratories Inc.
    --  Bio-Techne
    --  Dxcover Ltd.
    --  Exact Sciences Corp.
    --  F. Hoffmann-La Roche Ltd.
    --  Freenome
    --  Guardant Health
    --  Illumina Inc.
    --  Myriad Genetics Inc.
    --  Natera Inc.
    --  Neogenomics Laboratories
    --  Novigenix SA
    --  Personalis Inc.
    --  Qiagen
    --  Thermo Fisher Scientific Inc.

Related reports include:

Global DNA Sequencing: Research, Applied and Clinical Markets: The global DNA sequencing market covers research, practical applications, and medical use, helping scientists study genes, develop new treatments, and diagnose diseases. As technology improves, DNA sequencing is becoming faster, more affordable, and more widely used in healthcare and research.

Exosome Diagnostics, Therapeutics and Research Tools: Global Markets: Exosome diagnostics and therapeutics involve using tiny particles released by cells to detect diseases and develop new treatments. The global market for these tools is growing as researchers explore their potential in cancer detection, drug delivery, and other medical applications.

Purchase a copy of the report direct from BCC Research.

For further information on these reports or to purchase one, please contact info@bccresearch.com.

About BCC Research
BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help readers make informed business decisions, free of noise and hype.

Contact Us
Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA
Email: info@bccresearch.com
Phone: +1 781-489-7301

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library.

Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

Logo: https://mma.prnewswire.com/media/2183242/5317069/BCC_Research_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/liquid-biopsy-market-boom-tools-services-and-diagnostics-unveiled-302454382.html

SOURCE BCC Research LLC